First-in-Human, Dose Finding, Open Label Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)

Trial Profile

First-in-Human, Dose Finding, Open Label Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2017

At a glance

  • Drugs NP G2 044 (Primary)
  • Indications Solid tumours
  • Focus Adverse reactions; First in man
  • Sponsors Novita Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2017 Status changed from not yet recruiting to recruiting.
    • 30 Oct 2017 Planned initiation date changed from 15 Oct 2017 to 3 Nov 2017.
    • 29 Sep 2017 Planned initiation date changed from 1 Sep 2017 to 15 Oct 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top